Edwards Lifesciences Corporation

(New York Stock Exchange)
Back to all articles
Bullish +62

Curious about Edwards Lifesciences (EW) Q3 Performance? Explore Wall Street Estimates for Key Metrics

Earnings report AI-generated analysis

πŸ“ˆ Analysts project Edwards Lifesciences quarterly earnings of $0.73 per share, representing a 9% year-over-year increase.

πŸ’° Revenue is estimated to reach $1.68 billion, an 8% rise from the same quarter last year.

πŸ“Š The consensus EPS estimate has been adjusted upward by 0.1% over the past 30 days.

❀️ Net sales for Transcatheter Mitral and Tricuspid Therapies are forecast at $195.98 million, up 35% year-over-year.

πŸ”ͺ Surgical Structural Heart revenue is expected to hit $267.05 million, a 3.5% increase from the prior quarter.

🩺 Transcatheter Aortic Valve Replacement sales are projected at $1.21 billion, reflecting a 5.1% year-over-year change.

πŸ“‰ Edwards Lifesciences shares returned +10.9% over the past month versus the S&P 500 composite's +0.7% gain.

βš–οΈ The stock currently holds a Zacks Rank #3 (Hold), indicating potential alignment with overall market performance.

Bullish Signals
  • Analysts project quarterly earnings of $0.73 per share, representing a significant 9% year-over-year increase.
  • Revenue is forecast to reach $1.68 billion, marking an 8% growth from the prior-year quarter.
  • The consensus EPS estimate has been revised upward by 0.1% over the past month, signaling improved analyst confidence.
  • Transcatheter Mitral and Tricuspid Therapies are expected to generate $195.98 million in net sales, a robust 35% year-over-year surge.
  • Edwards Lifesciences shares have outperformed the broader market with a +10.9% return over the past month.
Full Analysis
Wall Street analysts project Edwards Lifesciences (EW) to report quarterly earnings of $0.73 per share, marking a 9% year-over-year increase. Revenue is estimated at $1.68 billion, representing an 8% rise from the prior-year quarter. Over the past 30 days, the consensus EPS estimate has been adjusted upward by 0.1%, reflecting analysts' collective reassessment of their initial projections. Analyst forecasts for specific product groups indicate strong growth in Edwards' structural heart therapies. Net sales for Transcatheter Mitral and Tricuspid Therapies are expected to reach $195.98 million, a 35% increase year-over-year. Surgical Structural Heart revenue is projected at $267.05 million, up 3.5%, while Transcatheter Aortic Valve Replacement sales are estimated at $1.21 billion, reflecting a 5.1% gain. In the broader market context, Edwards Lifesciences shares have outperformed significantly over the past month, returning +10.9% compared to the Zacks S&P 500 composite's +0.7% change. Despite this recent momentum, the stock currently carries a Zacks Rank #3 (Hold), suggesting that future performance may align more closely with overall market trends in the near future.